期刊文献+

卡培他滨联合草酸铂治疗晚期复发或转移性大肠癌的疗效观察 被引量:4

下载PDF
导出
摘要 目的观察卡培他滨联合草酸铂治疗复发或转移性大肠癌的近期疗效和相关症状改善(DRSI)及毒副反应。方法卡培他滨1250mg/m2,2次/d口服,第1~14天;草酸铂130mg/m2溶入5%葡萄糖注射液500ml中静脉滴注6h,第1天,同时静滴三磷酸胞苷二钠60~80mg/d,用草酸铂前1天开始使用,共用3天;21d为1周期;至少连用4~6个周期,停药4周后评价疗效。结果42例患者中CR3例(7.1%)、PR18例(42.9%)、SD15例(35.7%)、PD6例(14.3%),RR50.0%。30例症状改善。主要毒副反应为恶心、呕吐、腹泻、血白细胞减少、手足综合征、末梢神经异常、口腔黏膜炎;但程度均较轻,主要为Ⅰ度、Ⅱ度,经对症处理后很快恢复。结论卡培他滨和草酸铂联合方案治疗复发或转移性大肠癌的疗效确切,安全有效,可明显改善患者症状,提高患者的生活质量,毒副反应小,患者可以耐受。
出处 《广西医学》 CAS 2006年第10期1554-1556,共3页 Guangxi Medical Journal
  • 相关文献

参考文献9

  • 1Simmonds PC.Palliative chemotherapy for advanced colorectal cancer:systematic review and metar analysis[J].BMJ,2000,321(7 260):531~535.
  • 2Schmoll HJ,Cassidy J.Integrating oxaliplatin into the management of colorectal cancer[J].Oncologist,2001,6(Suppl 4):24~28.
  • 3Borner MM,Dietrich D,Stupp R,et al.Phase Ⅱ study of capecitabine and oxaliplatin in first and second-line treatment of advanced or metastatic colorectal cancer[J].Clin Oncol,2002,20(7):1 759~1 766.
  • 4林万隆,陈强.奥沙利铂的药理作用及临床应用[J].中国肿瘤临床,2000,27(11):872-874. 被引量:333
  • 5Grothy A.Oxaliplatin safety profile:neurotixicity[J].Semin Oncol,2003,30(Suppl 15):5~13.
  • 6Jamieson SM,Liu J,Hsu T,et al.Palitaxel induces neuclolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity[J].Br J Cancer,2003,88(12):1 942~1 947.
  • 7姜斌,王梅,龚圣济,姚宝娣.卡培他滨治疗结直肠癌肝转移的临床观察[J].药学服务与研究,2004,4(4):321-321. 被引量:3
  • 8Schuller J,Cassidy J,Dumont E,et al.Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients[J].Cancer Chemother Pharmacol,2000,45(4):291.
  • 9万玉良,姜玉石,王宁,李红光.术前希罗达化疗对结直肠癌组织胸苷磷酸化酶表达的影响[J].现代中西医结合杂志,2004,13(22):2962-2963. 被引量:2

二级参考文献15

  • 1[1]Gambill BD. First-line capecitabine is as effective as 5-fluorouracil/leucovorin in treating advanced colorectal cancer [J]. Clin Colorectal Cancer, 2001,1 (1): 18.
  • 2[2]Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue[J]. Eur J Cancer,1998,34(3):1274.
  • 3[3]Gerbrecht BM. Current Canadian experience with capecitabine: partnering with patients to optimize therapy[J].Cancer Nurs,2003, 26(2):161.
  • 4[4]Rothenberg ML. Current status of capecitabine in the treatment of colorectal cancer[J]. Oncology, 2002, 16 (12Suppl 14): 16.
  • 5[5]Eng C, Kindler HL, Schilsky RL. Oral fluoropyrimidine treatment of colorectal cancer [J]. Clin Colorectal Cancer,2001,1(2):95.
  • 6Miwa M, Ura M, Nishida M, et al. Design of novel oral fluoropyrimidine carbamate, capecitabine, which generates 5 - fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue[J]. Eur J Cancer, 1998,34(8): 1274 - 1281
  • 7Okamoto E, Ossaki M,Kase S, et al. Thymidine phosphorylase ex pression causes both the increase of intratumoral microvessels and decrease of apoptosis in human esophageal carcinomas [J]. Pathol Int,2001,51(3):158-164
  • 8Nishimura G,Terada I,Kobayashi T, et al. Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'- deoxy- 5-fluorouridine as adjuvant chemotherapy[J]. Oncol Rep, 2002, 9(
  • 9Mimori K,Ueo H,Kuroki T,et al. Prediction of 5' - deoxy- 5-fluorouridine sensitivity in colorectal cancer cases by thymidine phosphorylase activity and preliminary identification of susceptibility related genes[J]. Oncol Rep,2004,32(7) :762 - 767
  • 10Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients [J]. Cancer Chemother Pharmacol, 2000,45(4):292 - 297

共引文献333

同被引文献41

引证文献4

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部